Governance Legend Biotech Corporation

LEGN

US52490G1022

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 21:00:00 20/06/2025 BST			5-day change	1st Jan Change
34.00 ^USD	-2.52%		-7.68%	+4.49%

06-16	SPIC Yuanda Environmental Protection Names Chief Accountant	MT
06-05	Legend Biotech Corporation Appoints Peter Salovey as Lead Independent Director, Effective June 5, 2025	CI

Executive Committee: Legend Biotech Corporation

Manager

Positions heldSince

Ying Huang

52 year

Chief Executive Officer

20/09/2020

Jim Pepin

General Counsel

31/10/2023

Elaine Qian

Human Resources Officer

Mythili Koneru

47 year

Chief Tech/Sci/R&D Officer

10/04/2023

Tracy Luo

Chief Tech/Sci/R&D Officer

30/04/2018

Guowei Fang

Chief Tech/Sci/R&D Officer

28/02/2022

Jessie Yeung

40 year

Director of Finance/CFO	01/01/2025
Investor Relations Contact	31/12/2018

Yuhong Qiu

General Counsel

30/04/2018

Composition of the Board of Directors: Legend Biotech Corporation

Director

CommitteesSince

Fang Liang Zhang

60 year

Chairman

01/08/2022

Ye Wang

56 year

Compensation Committee	01/08/2022
Nominating Committee	10/03/2025
Audit Committee Chair	28/05/2025
Governance Committee Chair	01/08/2022
Nominating Committee Chair	01/08/2022

Tomas Jan Heyman

69 year

Audit Committee	29/06/2020
Governance Committee Chair	29/06/2020
Nominating Committee Chair	29/06/2020
Governance Committee	30/05/2023

Wai Man Yau

49 year

Governance Committee
Nominating Committee
Audit Committee Chair	30/04/2020

Corazon Sanders

68 year

Audit Committee
Compensation Committee

Xiao Hui Ji

63 year

Audit Committee
Compensation Committee Chair	30/04/2020

Patrick Casey

69 year

Governance Committee
Nominating Committee

Li Zhu

75 year

Director/Board Member

22/11/2020

Ying Huang

52 year

Director/Board Member

29/12/2021

Li Mao

68 year

Director/Board Member	01/08/2022
Independent Dir/Board Member	01/08/2022

Peter Salovey

67 year

Director/Board Member	08/08/2024
Independent Dir/Board Member	08/08/2024

Latest Appointments: Legend Biotech Corporation

SPIC Yuanda Environmental Protection Names Chief Accountant	06-16	MT
Legend Biotech Corporation Appoints Peter Salovey as Lead Independent Director, Effective June 5, 2025	06-05	CI
Karyopharm Therapeutics Names Lori Macomber CFO	01-02	MT
Top Midday Decliners	12-24	MT
Legend Biotech CFO Lori Macomber to Resign, Jessie Yeung Named Interim CFO	12-24	MT
Legend Biotech Corporation Appoints Jessie Yeung as Interim Principal Accounting Officer, Effective January 2, 2025	12-23	CI
Legend Biotech Corporation Appoints Alan Bash as President of CARVYKTI®	11-04	CI

More news

Former Officers and Directors: Legend Biotech Corporation

Insider

Positions held

SinceUntil

Lori Macomber

Comptroller/Controller/Auditor	31/08/2019	29/02/2020
Director of Finance/CFO	08/05/2022	01/01/2025
Corporate Officer/Principal	29/02/2020	08/05/2022

Steven J. Gavel

Corporate Officer/Principal

31/07/2018

31/12/2024

Tina Carter

Public Communications Contact

30/06/2021

30/11/2023

Liz Gosen

Chief Tech/Sci/R&D Officer

30/04/2019

30/11/2023

Marc L. Harrison

General Counsel

31/12/2021

30/06/2023

Lida Pacaud

Chief Tech/Sci/R&D Officer

31/12/2020

31/05/2023

Meeta Chatterjee

Corporate Officer/Principal

28/02/2019

31/10/2022

Robert Sexton

Corporate Officer/Principal

31/03/2019

30/09/2022

Frank Fan

Chief Tech/Sci/R&D Officer	31/12/2013	29/03/2022
Founder	-	29/03/2022

John Tomtishen

Corporate Officer/Principal

10/10/2021

Crystal Chen

Public Communications Contact

31/12/2020

Syed Rizvi

Chief Tech/Sci/R&D Officer

31/05/2018

31/10/2020

Yuan Xu

Director/Board Member	28/02/2018	31/07/2020
Chief Executive Officer	28/02/2018	31/07/2020

Qi Pan

Chief Tech/Sci/R&D Officer

31/07/2017

31/12/2017

Zuie Chin Huang

Founder

Joanne Choi

Investor Relations Contact

Age distribution of managers

Parity Men Women

Male	16
Female	3

Of which Executive Committee

Male	6
Female	2

Of which Directors

Male	10
Female	1

Revisions

Revenue revisions (1 year)

Revenue revisions (4 months)

Revenue revisions (1 month)

EPS revisions (1 year)

EPS revisions (4 months)

ESG MSCI

ESG

Environment

Social

Governance

Controversy

Ethical controversies

Human rights controversies

Tax subsidies controversies

Sharia compliant

Legend Biotech Corporation is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of cell therapies for oncology and other indications. Its lead product candidate, ciltacabtagene autoleucel (cilta-cel), referred to as LCAR- B38M, is an autologous chimeric antigen receptor (CAR-T) cell therapy that targets the B-cell maturation antigen (BCMA), which is a highly expressed protein in several hematologic malignancies, including multiple myeloma (MM). In addition to cilta-cel, the Company has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. It is also engaged in developing an allogeneic gamma delta CAR-T product candidate and an allogeneic CAR-NK product candidate targeting BCMA for MM.

Employees

2,700

Sector

Biotechnology & Medical Research

Calendar

08-28 - Q2 2025 Earnings Release (Projected)

More about the company